Saudi Press

Saudi Arabia and the world
Friday, Oct 03, 2025

A TikTok Trend Sold Out Ozempic, Leaving People With Diabetes Dizzy, Scared

A TikTok Trend Sold Out Ozempic, Leaving People With Diabetes Dizzy, Scared

Ozempic, an injection that keeps blood sugar levels in check for patients with type 2 diabetes, has been in shortage for about four months, according to the database maintained by the US Food and Drug Administration.
For more than a month, Shane Anthony, a 57-year-old auto mechanic, hasn't been able to get his diabetes medication.

Ozempic, an injection that keeps blood sugar levels in check for patients with type 2 diabetes, has been in shortage for about four months, according to the database maintained by the US Food and Drug Administration, and is backordered at Anthony's Seattle pharmacy. 

Without the Novo Nordisk A/S-made prescription, he has suffered recurring dizzy spells while repairing cars. Alternative medications are either out of stock or not covered by his insurance.

While increased demand and supply chain delays have left multiple medicines from the antibiotic amoxicillin to Adderall in short supply, the reason for a lack of certain diabetes drugs is unusual: doctors are prescribing them to non-diabetics who want to use them for weight loss.

"All these famous people, stars who don't need to lose weight, are going and getting it," Mr Anthony said. "I need it to stay healthy and not die."

For the more than 35 million people who live with type 2 diabetes, the shortages have added yet another layer to managing an already complicated and costly chronic illness. They've also exposed weaknesses in America's use of off-label prescribing, which allows physicians to hand out drugs to treat a different condition than the one for which they were officially approved. When those medications are hard to find because of celebrity and social-media hype, patients with diabetes suffer.

Ozempic, known generically as semaglutide, is one of a class of diabetes drugs known as GLP-1 receptor agonists that have been around for nearly two decades. It was first approved in the US in 2017 for use in those with type 2 diabetes. Ozempic mimics a hormone involved in appetite and eating, helping to stimulate insulin production and lower patients' blood glucose levels. It also often leads to them shedding pounds.

Francisco Prieto, a family physician in Sacramento, California, sees at least one person with diabetes per week who is having trouble filling their prescription for Ozempic. Patients will call multiple pharmacies and drive around town to see if it's in stock, but some still haven't been able to get it, said Mr Prieto, who also does advocacy work for the American Diabetes Association.

Recently, one of Mr Prieto's patients experienced a three week-long delay filling a prescription for Trulicity, a similar type 2 diabetes drug that's also seeing increased demand for weight-loss use. Mr Prieto prescribed a lower dose, and recommended that the patient take two injections a week. He described the compromise as "less than ideal, but better than nothing."

Without their medication, patients with diabetes could be at higher risk for things like heart disease, heart attacks, infections like Covid, disability and even death, Mr Prieto said. And while getting a different prescription can be an option, it can come with new hurdles, including insurance coverage and closer monitoring in case the alternative doesn't work as well.

Both new and established users of Ozempic are being affected by periodic supply disruptions. A representative for manufacturer Novo Nordisk said in a statement that the issues are expected to continue through January. The company cited "incredible demand" and short-term capacity limitations at some factories, and said that it is investing to grow manufacturing.

Higher doses of Ozempic that aren't usually given to new patients are available, and Novo's other GLP-1 drugs for diabetes aren't in short supply, though there may be normal delays at pharmacies, the company said. In an earnings presentation in November, Novo said that its sales, as measured in Danish kroner, grew by 26% in the first nine months of the year, largely because of higher demand for Ozempic and other diabetes drugs.

Eli Lilly & Co.'s Trulicity and Mounjaro, both approved to treat type 2 diabetes, are also seeing demand that's resulting in backorders on some doses at pharmacies, a Lilly spokeswoman said. The drugs were listed as being in shortage by the FDA on Thursday. Lilly isn't having supply chain or manufacturing issues, though the company is working to double manufacturing capacity for the category by the end of next year, the spokeswoman said.

Though off-label prescribing is common and legal in the US, it has long created issues. In the early months of the Covid-19 pandemic, for example, people took an unproven drug called hydroxychloroquine, which they believed helped with the virus. That created shortages for patients who take it for lupus and arthritis.

Ozempic is a good candidate for off-label use for obesity, which is also considered a disease and can put people at higher risk for other conditions: official ads for the drug say patients lose on average up to 12 pounds when taking it. It's just not clear that everyone using the drug has a medical need for it.

On TikTok, some videos featuring the hashtag Ozempic have been viewed more than a million times. Medical spas offer the prescription alongside shots of Botox and laser hair removal. Sponsored ads on Google promise weight loss with no exercise or dieting. A plastic surgeon brags on Facebook about using the drug to lose 10 pounds she gained during Covid, and says to call her office to get started.

The FDA doesn't regulate this kind of prescribing. That means many decisions about what to do are up to individuals.

"Which disease is most acute and most severe? Which has alternatives? How adequate are those alternatives?" said Holly Fernandez Lynch, an assistant professor of medical ethics and law at the University of Pennsylvania. "These are the kinds of questions that would help you figure out which patients should have priority access."

Fernandez Lynch said a judgement would depend on the individual case. But those who just want to lose a few pounds shouldn't take a scarce resource that someone else needs, she said.

In Seattle, Mr Anthony has recently been able to get an alternative diabetes drug. It's a much older treatment that requires twice-a-day injections before mealtimes, which he didn't have to think about with Ozempic and has found challenging. It's too soon to know how well it will work for him.

Mr Prieto, the family physician, said his patients are scared and alarmed about the shortage - especially if the drug has really helped improve their health.

"Right now, diabetes is the greater danger, and those folks have a higher need for the drug," he said.
Newsletter

Related Articles

Saudi Press
0:00
0:00
Close
Altman Says GPT-5 Already Outpaces Him, Warns AI Could Automate 40% of Work
Trump Organization Teams with Saudi Developer on $1 Billion Trump Plaza in Jeddah
Electronic Arts to Be Taken Private in Historic $55 Billion Buyout
Colombian President Petro Vows to Mobilize Volunteers for Gaza and Joins List of Fighters
Nvidia and Abu Dhabi’s TII Launch First AI-&-Robotics Lab in the Middle East
UK, Canada, and Australia Officially Recognise Palestine in Historic Shift
New Eye Drops Show Promise in Replacing Reading Glasses for Presbyopia
Dubai Property Boom Shows Strain as Flippers Get Buyer’s Remorse
Top AI Researchers Are Heading Back to China as U.S. Struggles to Keep Pace
JWST Data Brings TRAPPIST-1e Closer to Earth-Like Habitability
UAE-US Stargate Project Poised to Make Abu Dhabi a Global AI Powerhouse
Trump and Starmer Clash Over UK Recognition of Palestinian State Amid State Visit
Saudi Arabia cracks down on music ‘lounges’ after conservative backlash
Saudi Arabia Signs ‘Strategic Mutual Defence’ Pact with Pakistan, Marking First Arab State to Gain Indirect Access to Nuclear Strike Capabilities in the Region
Sam Altman sells the 'Wedding Estate' in Hawaii for 49 million dollars
Turkish car manufacturer Togg Enters German Market with 5-Star Electric Sedan and SUV to Challenge European EV Brands
World’s Longest Direct Flight China Eastern to Launch 29-Hour Shanghai–Buenos Aires Direct Flight via Auckland in December
New OpenAI Study Finds Majority of ChatGPT Use Is Personal, Not Professional
Kuwait opens bidding for construction of three cities to ease housing crunch.
This Week in AI: Meta’s Superintelligence Push, xAI’s Ten Billion-Dollar Raise, Genesis AI’s Robotics Ambitions, Microsoft Restructuring, Amazon’s Million-Robot Milestone, and Google’s AlphaGenome Update
Indian Student Engineers Propose “Project REBIRTH” to Protect Aircraft from Crashes Using AI, Airbags and Smart Materials
Could AI Nursing Robots Help Healthcare Staffing Shortages?
Turkish authorities seize leading broadcaster amid fraud and tax investigation
Qatari prime minister says Netanyahu ‘killed any hope’ for Israeli hostages
Apple Introduces Ultra-Thin iPhone Air, Enhanced 17 Series and New Health-Focused Wearables
Big Oil Slashes Jobs and Investments Amid Prolonged Low Crude Prices
Social Media Access Curtailed in Turkey After CHP Calls for Rallies Following Police Blockade of Istanbul Headquarters
Did the Houthis disrupt the internet in the Middle East? Submarine cables cut in the Red Sea
Gold Could Reach Nearly $5,000 if Fed Independence Is Undermined, Goldman Sachs Warns
Uruguay, Colombia and Paraguay Secure Places at 2026 World Cup
Trump Administration Advances Plans to Rebrand Pentagon as Department of War Instead of the Fake Term Department of Defense
Tether Expands into Gold Sector with Profit-Driven Diversification
Trump’s New War – and the ‘Drug Tyrant’ Fearing Invasion: ‘1,200 Missiles Aimed at Us’
At the Parade in China: Laser Weapons, 'Eagle Strike,' and a Missile Capable of 'Striking Anywhere in the World'
Information Warfare in the Age of AI: How Language Models Become Targets and Tools
Israeli Airstrike in Yemen Kills Houthi Prime Minister
After the Shock of Defeat, Iranians Yearn for Change
YouTube Altered Content by Artificial Intelligence – Without Permission
Iran Faces Escalating Water Crisis as Protests Spread
More Than Half a Million Evacuated as Typhoon Kajiki Heads for Vietnam
HSBC Switzerland Ends Relationships with Over 1,000 Clients from Saudi Arabia, Lebanon, Qatar, and Egypt
Sharia Law Made Legally Binding in Austria Despite Warnings Over 'Incompatible' Values
Dogfights in the Skies: Airbus on Track to Overtake Boeing and Claim Aviation Supremacy
Tim Cook Promises an AI Revolution at Apple: "One of the Most Significant Technologies of Our Generation"
Are AI Data Centres the Infrastructure of the Future or the Next Crisis?
Miles Worth Billions: How Airlines Generate Huge Profits
Zelenskyy Returns to White House Flanked by European Allies as Trump Pressures Land-Swap Deal with Putin
Beijing is moving into gold and other assets, diversifying away from the dollar
Cristiano Ronaldo Makes Surprise Stop at New Hong Kong Museum
Zelenskyy to Visit Washington after Trump–Putin Summit Yields No Agreement
×